Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Carducci

Showing results (201-210 of 386) with videos related to

Pageof 39
Sort By:
Journal of Cancer Survivorship : Research and Practice|March 1, 2014
It's who you know: patient-sharing, quality, and costs of cancer survivorship careCraig Evan Pollack, Kevin D Frick, Robert J Herbert, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 7, 2009
Concordance of cancer patients' function, symptoms, and supportive care needsClaire F Snyder, Elizabeth Garrett-Mayer, Amanda L Blackford, et al.
Clinical Genitourinary Cancer|May 27, 2017
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])Roberto Pili, Opeyemi Jegede, Michael A Carducci, et al.
Biochemical and Biophysical Research Communications|July 30, 2013
Screening assay for blood vessel maturation inhibitorsChenglai Fu, Anita van der Zwan, Stephanie Gerber, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 26, 2013
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitorsMichel D Wissing, Janet Mendonca, Madeleine S Q Kortenhorst, et al.
Urology|April 5, 2008
Effect of DNA methylation on identification of aggressive prostate cancerJoshi J Alumkal, Zhe Zhang, Elizabeth B Humphreys, et al.
Clinical Pharmacology and Therapeutics|January 10, 2008
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurementsA C Hooker, A J Ten Tije, M A Carducci, et al.
American Journal of Clinical Oncology|August 8, 2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinomaVictoria J Sinibaldi, Kathy Elza-Brown, Jill Schmidt, et al.
JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Pageof 39

Showing results (201-210 of 386) with videos related to

Sort By:
Pageof 39
Journal of Cancer Survivorship : Research and Practice|March 1, 2014
It's who you know: patient-sharing, quality, and costs of cancer survivorship careCraig Evan Pollack, Kevin D Frick, Robert J Herbert, et al.
Cancer Chemotherapy and Pharmacology|October 25, 2011
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trialEmmanuel S Antonarakis, Michael A Carducci, Mario A Eisenberger, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|August 7, 2009
Concordance of cancer patients' function, symptoms, and supportive care needsClaire F Snyder, Elizabeth Garrett-Mayer, Amanda L Blackford, et al.
Clinical Genitourinary Cancer|May 27, 2017
A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805])Roberto Pili, Opeyemi Jegede, Michael A Carducci, et al.
Biochemical and Biophysical Research Communications|July 30, 2013
Screening assay for blood vessel maturation inhibitorsChenglai Fu, Anita van der Zwan, Stephanie Gerber, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|July 26, 2013
Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitorsMichel D Wissing, Janet Mendonca, Madeleine S Q Kortenhorst, et al.
Urology|April 5, 2008
Effect of DNA methylation on identification of aggressive prostate cancerJoshi J Alumkal, Zhe Zhang, Elizabeth B Humphreys, et al.
Clinical Pharmacology and Therapeutics|January 10, 2008
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurementsA C Hooker, A J Ten Tije, M A Carducci, et al.
American Journal of Clinical Oncology|August 8, 2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinomaVictoria J Sinibaldi, Kathy Elza-Brown, Jill Schmidt, et al.
JAMA Oncology|May 26, 2018
Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical TrialAndrew J Armstrong, Aseem Anand, Lars Edenbrandt, et al.
Pageof 39